Publications by authors named "S Runswick"

Claim this Profile
P
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
Anna Morena D'Alise, Guido Leoni, Gabriella Cotugno, Loredana Siani, Rosa Vitale, Sarah Runswick

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
M E Robson, N Tung, P Conte, S-A Im, E Senkus, S Runswick

Ann Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib.
James R Bradford, Matthew Farren, Steve J Powell, Sarah Runswick, Susie L Weston

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, Sarah Runswick, Darren R Hodgson

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Sarah Runswick

N Engl J Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis